Q&A: MindMed’s Dan Karlin Discusses Phase II Win and the Therapeutic Potential of Psychedelics

By /

After reporting positive mid-stage results for its LSD-based therapy for generalized anxiety disorder, MindMed’s chief medical officer sat down with BioSpace to discuss the path forward.

Scroll to Top